Clinical trials: Enlarged Prostate (BPH)
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS)
Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.
This is a prospective, randomized, open-label, parallel-group post-market clinical trial (PMCT). The overall objective of this PMCT is to compare the effectiveness, durability, and patient-centered outcomes of the Zenflow Spring…
- Conditions
- Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS), Enlarged Prostate
- Trial name
- NCT07797348
- Testing
- Zenflow Arm: Zenflow Spring System implant procedure, Medical Therapy Tamsulosin
- Volunteers
- 110 people
- Sponsor
- Zenflow, Inc.
Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
This non-randomized, interventional study will be conducted in a general practice setting to assess the utility of a benign prostatic enlargement (BPE)/benign prostatic obstruction (BPO) screening tool in conjunction with…
- Trial name
- NCT02757963
- Testing
- Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool
- Where
- 45 sites in France, Germany and 3 more
- Volunteers
- 1,679 people
- Sponsor
- GlaxoSmithKline
BPH, BOO - Bladder Outflow Obstruction
Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients.
This study evaluates the safety and efficacy of use of the Butterfly Medical's prostatic retraction device in Benign Prostatic Hyperplasia (BPH) Patients.
- Trial name
- NCT03912558
- Testing
- Butterfly device implantation
- Where
- 4 sites in Israel
- Volunteers
- 92 people
- Sponsor
- Butterfly Medical Ltd.
Benign Prostatic Hyperplasia
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)
Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control.
- Trial name
- NCT07619105
- Testing
- Vesomni
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Korea, Inc.
Benign Prostatic Hyperplasia
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the…
- Trial name
- RAPID-III (NCT06849258)
- Testing
- FloStent
- Where
- 20 sites in United States, Australia
- Volunteers
- 215 people
- Sponsor
- Rivermark Medical
Prostate
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
- Trial name
- NCT00648323
- Testing
- Doxazosin mysylate GITS
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Benign Prostatic Hyperplasia (BPH)
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
This trial is conducted to evaluate the effect of etonogestrel in comparison to placebo on: the prostate volume and the urinary complaints; the urinary flow and the urinary volume in the bladder after voiding; the progression of…
- Trial name
- NCT00651807
- Testing
- etonogestrel
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- Organon and Co
Prostatic Hyperplasia
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin…
- Trial name
- CONDUCT (NCT01294592)
- Testing
- Dutasteride plus tamsulosin, tamsulosin
- Where
- 80 sites in France, Germany and 6 more
- Volunteers
- 742 people
- Sponsor
- GlaxoSmithKline
Urinary Retention, Prostatic Hyperplasia
Clinical Trial in Males With BPH (Enlarged Prostate)
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. Free study-related medical care provided.
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00029822
- Testing
- Alfuzosin (SL770499)
- Where
- 54 sites in United States, Australia and 15 more
- Volunteers
- 1,522 people
- Sponsor
- Sanofi
Prostatic Hyperplasia
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
This retrospective study aims to quantify the relationship between 5-alpha-reductase inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention (AUR) or prostate surgery in patients with benign…
- Trial name
- NCT01334723
- Testing
- Adherent with 5-alpha-reductase inhibitor (5ARI) therapy, Non-adherent to 5ARI therapy
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
The purpose of this study is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) for prostatic artery embolization (PAE) using Embosphere…
- Trial name
- NCT01789840
- Testing
- Embosphere Microspheres, TURP
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Merit Medical Systems, Inc.
Benign Prostatic Hyperplasia (BPH)
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00945490
- Testing
- NX-1207
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Prostate Disease, BPH
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
Multi-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug.
- Conditions
- Prostate Disease, BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00037141
- Testing
- dehydrated alcohol
- Volunteers
- 150 people
- Sponsor
- American Medical Systems
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).
- Trial name
- REZUM (NCT01912339)
- Testing
- Rezum System, Rigid Cystoscopy
- Where
- 15 sites in United States
- Volunteers
- 197 people
- Sponsor
- Boston Scientific Corporation
Prostatic Hyperplasia
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged…
- Trial name
- NCT01390870
- Testing
- 5ARI or AB or Combination Therapy (5ARI + AB)
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
The purpose of this study is to evaluate the safety and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- PLUS-1 (NCT01966614)
- Testing
- PRX302
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 479 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).
- Trial name
- TRIUMPH-1 (NCT00889707)
- Testing
- PRX302
- Where
- 9 sites in Canada
- Volunteers
- 92 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00918983
- Testing
- NX-1207
- Where
- 41 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation